Memphasys

Memphasys OCF Margin

The Operating Cash Flow Margin of Memphasys (MEM.AX) as of Oct 19, 2026 is -909.62 %. In the previous year, Operating Cash Flow Margin was -457.33 % — a change of 98.90% (lower).

OCF Margin

-909.62 %

YoY

98.90%

Last updated:

Operating Cash Flow Margin of Memphasys is 2026 -909.62 % . Operating Cash Flow Margin of Memphasys was 2025 -457.33 % . It decreases by 98.90% lower compared to the previous year.

The Memphasys OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2015
-3,031.51 AUD
Jan 1, 2016
-1,986.52 AUD
Jan 1, 2021
21.14 AUD
Jan 1, 2022
1,148.58 AUD
Jan 1, 2023
-9,151.45 AUD
Jan 1, 2024
-5,385.63 AUD
Jan 1, 2025
-457.33 AUD
Jan 1, 2026
-909.62 AUD
The Memphasys OCF Margin history
YEAROCF MarginYoY
-909.62 %+98.90%
-457.33 %-91.51%
-5,385.63 %-41.15%
-9,151.45 %-896.76%
1,148.58 %+5,333.40%
21.14 %-101.06%
-1,986.52 %-34.47%
-3,031.51 %+2,639.25%
-110.67 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Memphasys Stock analysis

What does Memphasys do? Memphasys Ltd, listed on the Australian Securities Exchange under the ticker MEM.AX, is a life sciences company headquartered in Homebush West, New South Wales. The company went public via an IPO on May 14, 2007. Memphasys operates within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company focuses on developing medical devices, diagnostics, and media for applications in assisted reproduction technology (ART) for both humans and animals. Its product pipeline includes several developments, such as Felix, ROSA, and AI-Port. Felix is a patented, automated device designed to separate high-quality sperm from semen for human in vitro fertilization (IVF) procedures, aiming to avoid DNA damage. ROSA functions as an in vitro diagnostic tool to evaluate semen and blood samples for oxidative stress. AI-Port is a system for storing and transporting animal semen for artificial insemination (AI) in livestock, capable of maintaining semen viability for up to four days without freezing, which is a common practice in standard AI procedures. The company's products target global markets, particularly in the field of reproductive biotechnology, with specific applications in both human and animal reproductive health. Memphasys operates with a focus on innovation in reproductive technology, leveraging proprietary media and diagnostic tools to address challenges in assisted reproduction. Memphasys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Memphasys stock

Operating Cash Flow Margin of Memphasys is -909.62 % in 2026.

Operating Cash Flow Margin of Memphasys changed from -457.33 % to -909.62 %, representing a 98.90% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Memphasys since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Memphasys with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Memphasys

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Memphasys